tardive dyskinesia/seizures

Lyen an sove nan clipboard la

Chwazi kalite sòt

Paj 1 soti nan 50 rezilta yo

Effects of zonisamide on tardive dyskinesia: a preliminary open-label trial.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Once developed, tardive dyskinesia (TD) is a challenging condition to treat. The recent evidence has indicated that zonisamide, an antiepileptic drug indicated for partial-onset seizures, may also have beneficial effects for ameliorating dyskinesia in Parkinson's disease. However, this finding has

Haloperidol-induced tardive dyskinesia in monkeys.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

In three cebus monkeys the chronic daily administration of haloperidol (0.5 mg/kg/day orally) created sedation and parkinsonism during the first 5-7 weeks. Later the animals developed signs reminiscent of acute dystonia, as seen in the clinic during treatment with neuroleptics. These signs were

Tardive dyskinesia in northern Israel: preliminary study.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Tardive dyskinesia (TD) is an iatrogenic syndrome caused by long-term treatment with neuroleptics and is characterized by abnormal involuntary movements in the orofacial region, lingual dyskinesia and in some cases dyskinesia also in the extremities, head and trunk. In the present study we found 20%

Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Chronic antipsychotic drug treatment may cause tardive dyskinesia (TD), a long-term movement disorder. Gamma-aminobutyric acid (GABA) agonist drugs, which have intense sedative properties and may exacerbate psychotic symptoms, have been used to treat TD. OBJECTIVE To determine the effects

Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Chronic antipsychotic drug treatment may cause tardive dyskinesia (TD), a long-term movement disorder. The gamma-aminobutyric acid (GABA) agonist drugs have been trialed as a treatment for TD, but these drugs have intense sedative properties and may exacerbate psychotic

Gamma-aminobutyric acid agonists for antipsychotic-induced tardive dyskinesia.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Chronic antipsychotic drug treatment may cause tardive dyskinesia (TD), a long-term movement disorder. Gamma-aminobutyric acid (GABA) agonist drugs, which have intense sedative properties and may exacerbate psychotic symptoms, have been used to treat TD. 1. Primary objectiveThe primary objective was

Clozapine in tardive dyskinesia.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Clozapine, which has had limited clinical testing in the U.S.A., was evaluated in 12 chronic schizophrenic patients with tardive dyskinesia. Its antipsychotic activity was again demonstrated and it suppressed the symptoms of tardive dyskinesia with a marked rebound occurring in these symptoms when

Neurologic complications of drugs. Tardive dyskinesias, neuroleptic malignant syndrome, and cocaine-related syndromes.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Drugs, either self-administered or prescribed by physicians, can result in substantial neurologic disability in psychiatric patients. It is clear that the use of neuroleptic agents to treat psychiatric illness may result in a variety of tardive movement disorders. Most commonly, these take the form

Drug-induced taste disorders.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Numerous drugs have the potential to adversely influence a patient's sense of taste, either by decreasing function or producing perceptual distortions or phantom tastes. In some cases, such adverse effects are long lasting and cannot be quickly reversed by drug cessation. In a number of cases,

Clozapine therapy in patients with neurologic illness.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE This review will analyze the use of clozapine in patients with neurologic illness. METHODS A review of the literature was performed. Attention is focused particularly on patients with seizure disorder, head injury, mental retardation, Parkinson's disease, Huntington's disease, tardive

A review of clinical trials of lithium in neurology.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Lithium has been put to clinical trials in no less than fifteen neurological disorders. They are Huntington's chorea, tardive dyskinesia, spasmodic torticollis, Tourette's syndrome, L-dopa induced hyperkinesia and the "on-off" phenomenon in parkinsonism, organic brain disorders secondary to

Deep brain stimulation: current status.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

In the last two decades, applications of deep brain stimulation (DBS) have expanded rapidly in the field of neurosciences. The most common indications for DBS are Parkinson's disease, medically refractory seizures, essential tremors, and primary dystonia. This device has also been used as an

Clozapine safety, 40 years later.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Clozapine is, and will remain in the coming years, an irreplaceable drug in psychiatry which has elective indication in treatment-resistant schizophrenia, suicide risk in schizophrenia spectrum disorders, aggressiveness or violence in psychiatric patients, psychosis in Parkinson's disease,

Burns in the disabled.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

A retrospective analysis of 812 patients admitted to the Ross Tilley Burn Centre between 1984 and 1992 resulted in 37 cases of burn injuries which were directly related to premorbid disabilities. The majority of these burns (83.8 per cent) occurred in the patient's home, most commonly as scald

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye